Valneva Files 6-K, Attaches Press Release as Exhibit 99.1
Ticker: VALN · Form: 6-K · Filed: Feb 5, 2024 · CIK: 1836564
| Field | Detail |
|---|---|
| Company | Valneva Se (VALN) |
| Form Type | 6-K |
| Filed Date | Feb 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: press-release, regulatory-filing, corporate-update
TL;DR
**Valneva just dropped a 6-K with a press release, check Exhibit 99.1 for the news!**
AI Summary
Valneva SE, a French biotech company, filed a 6-K on February 5, 2024, to announce a press release, which is attached as Exhibit 99.1. This filing indicates that Valneva is providing updated information to the market, likely regarding a material event or business development. Investors should pay attention to the content of Exhibit 99.1 to understand any new developments that could impact Valneva's stock price or future prospects.
Why It Matters
This filing signals that Valneva has new, important information for investors, which could influence their perception of the company's value and future performance.
Risk Assessment
Risk Level: low — The 6-K itself is a routine filing for foreign private issuers and doesn't inherently carry high risk, but the content of the attached press release (Exhibit 99.1) could introduce new risks or opportunities.
Analyst Insight
A smart investor would immediately locate and review Exhibit 99.1 to understand the specific news Valneva is communicating, as this will be the key driver of any market reaction.
Key Players & Entities
- Valneva SE (company) — the registrant filing the 6-K
- February 5, 2024 (date) — date of the report and press release issuance
- 001-40377 (other) — Commission File Number for Valneva SE
- 6, rue Alain Bombard (other) — business and mail address of Valneva SE
- 44800 Saint-Herblain, France (other) — city and country of Valneva SE's principal executive office
Forward-Looking Statements
- The content of Exhibit 99.1 will likely contain information regarding clinical trial results or regulatory approvals for one of Valneva's vaccine candidates. (Valneva SE) — medium confidence, target: Q1 2024
- Valneva's stock price will react significantly to the news contained in the attached press release, either positively or negatively. (Valneva SE) — high confidence, target: February 5, 2024
FAQ
What is the primary purpose of Valneva SE's 6-K filing on February 5, 2024?
The primary purpose of Valneva SE's 6-K filing on February 5, 2024, is to issue a press release, a copy of which is attached as Exhibit 99.1 and incorporated by reference into the filing.
What is Valneva SE's Commission File Number as stated in the filing?
Valneva SE's Commission File Number, as stated in the filing, is 001-40377.
Where is Valneva SE's principal executive office located, according to the filing?
According to the filing, Valneva SE's principal executive office is located at 6 rue Alain Bombard, 44800 Saint-Herblain, France.
Under which SEC Act is this Form 6-K filed?
This Form 6-K is filed under the Securities Exchange Act of 1934, pursuant to Rule 13a-16 or 15d-16.
Does Valneva SE file annual reports under Form 20-F or Form 40-F?
Valneva SE indicates by check mark that it files annual reports under cover of Form 20-F.
Filing Stats: 197 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-02-05 06:05:06
Filing Documents
- f6k_020524.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-000572.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Valneva SE (Registrant) Date: February 5, 2024 /s/ Thomas Lingelbach Thomas Lingelbach Chief Executive Officer and President